helenien

Adaptinol is a brand name for helenien (lutein dipalmitate), a carotenoid derivative historically used in ophthalmology. It was primarily indicated for the improvement of dark adaptation (night vision) and the treatment of various retinal degenerative conditions, including retinitis pigmentosa (tapetoretinal degeneration). The drug acts as a precursor that supports the regeneration of rhodopsin (visual purple) in the rod cells of the retina, thereby enhancing visual sensitivity in low-light environments. Developed and marketed by Bayer in the mid-20th century, Adaptinol was typically administered as an oral capsule. While it was a standard pharmacological intervention in Europe during the 1950s and 1960s, its clinical use as a prescription drug has largely been superseded by modern nutritional supplements containing lutein and zeaxanthin.

Brand names

Adaptinol

Other names

helenienelutein dipalmitatehelenienum